Table 2.

Summary of published case reports of generalized CSH treated in the era of novel agents

Reference	date of publication	Age	Sex	Underlying disease	Organ involvment	Evolution before diagnosis	Ig	Treatment	Haematological response	Organ response	Evolution
Boudhabhay [7]	2018	60	M	multiple myeloma	cornea, kidney	2 years	IgGkappa	bortezomib-lenalidomide-dexamethasone	PR	NO	End stage renal failure
Wu [8]	2017	48	M	multiple myeloma	kidney	Unknown	IgGkappa	bortezomib-cyclophosphamide-dexamethasone	VGPR	NO	End stage renal failure
Aline-Fardin[9]	2015	69	M	monoclonal gammopathy	mesenteric panniculitis, lympho node, kidney	6 months	LC kappa	bortezomib-DXM	VGPR	YES	Persistent remission (12 months)
Baird [10]	2015	53	F	lymphoplasmocytic lymphoma	lung, mediastinal lymph node, bone marrow	18 months	IgM lambda	bortezomib-cyclophosphamide-dexamethasone-rituximab	VGPR	YES	Remission
Hu [11]	2012	48	F	multiple myeloma	spleen, bone marrow	2 years	IgGkappa	bortezomib-thalidomide-dexamethasone-rituximab	VGPR	YES	Remission
Robak [12]	2002	54	M	lymphoplasmocytic lymphoma	spleen, bone marrow	1 year	IgAkappa	ritixmab	PR	NO	Pancytopenia

F Female; M Male; PR Partial response; VGPR Very good partial response